Skip to main content
KYMR logo

KYMR · Kymera Therapeutics, Inc. · Webcasts, Transcripts & Audio

Track KYMR — free
$115.31 -4.08 (-3.42%) At close · Nov 20 Q3 2026 earnings call transcript
Market Cap
$9.84B
Shares
85.37M
Volume · Nov 20 1.28M Avg daily vol (3M) 847.26K

Kymera Therapeutics, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Kymera Therapeutics, Inc. (KYMR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Earnings call
FY26 · Q3
2026-10-29
Kymera Therapeutics, Inc. (KYMR) Q3 2026 Earnings Call Transcript
Revenue
$0
▼ 100% YoY
Diluted EPS
$-1.32
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-09-15
Kymera Therapeutics, Inc. (KYMR) September 15, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-14
Kymera Therapeutics, Inc. (KYMR) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-09
Kymera Therapeutics, Inc. (KYMR) September 9, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-05
Kymera Therapeutics, Inc. (KYMR) Q2 2026 Earnings Call Transcript
Confident tone KT-621 Asthma and other type 2 indications Financial strength and runway Pediatric and label expansion strategy
Revenue
$65.00M
▲ 466.4% YoY
Diluted EPS
$-0.62
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Kymera Therapeutics, Inc. (KYMR) June 3, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-05-12
Kymera Therapeutics, Inc. (KYMR) May 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-04-30
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Revenue
$34.37M
▲ 55.5% YoY
Diluted EPS
$-0.71
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-03-12
Kymera Therapeutics, Inc. (KYMR) March 12, 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript
Confident tone KT-579 IRF5 Degrader for Lupus KT-621 STAT6 Degrader in Atopic Dermatitis and Asthma Enrollment Dynamics and Competition
Revenue
$2.87M*
▼ 61.2% YoY
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Kymera Therapeutics, Inc. (KYMR) Q3 2025 Earnings Call Transcript
Confident tone KT-621 STAT6 program BroADen Phase Ib data readout Asthma and pediatric opportunity
Revenue
$2.76M
▼ 26.1% YoY
Diluted EPS
$-0.94
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kymera Therapeutics, Inc. (KYMR) Q2 2025 Earnings Call Transcript
Confident tone KT-621 STAT6 program Phase IIb dose selection and trial planning Biomarker and clinical endpoint expectations
Revenue
$11.48M
▼ 55.3% YoY
Diluted EPS
$-0.95
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-09
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
Confident tone IRAF5 program introduction Immunology opportunity and market Clinical execution and milestones
Revenue
$22.10M
▲ 114.8% YoY
Diluted EPS
$-0.82
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Confident tone STAT6 / KT-621 program Clinical readout timing risks TYK2 / KT-295 program
Revenue
$7.39M*
▼ 84.6% YoY
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-10-31
Kymera Therapeutics, Inc. (KYMR) Q3 2024 Earnings Call Transcript
Confident tone KT-621 STAT6 degrader Phase 1 TYK2 program progression Partnership considerations for STAT6
Revenue
$3.74M
▼ 20.9% YoY
Diluted EPS
$-0.82
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Kymera Therapeutics, Inc. (KYMR) Q2 2024 Earnings Call Transcript
Confident tone KT-621 / STAT6 program KT-474 / IRAK4 program Pipeline and platform
Revenue
$25.65M
▲ 55.3% YoY
Diluted EPS
$-0.58
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-02
Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
Confident tone IRAK4 / KT-474 program STAT6 degrader KT-621 TYK2 degrader KT-294
Revenue
$10.29M
▲ 8.7% YoY
Diluted EPS
$-0.69
Gross margin
0.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Kymera Therapeutics, Inc. (KYMR) Q4 2023 Earnings Call Transcript
Confident tone STAT6 degrader (KT-621) IRAK4 / KT-474 program with Sanofi TYK2 degrader (KT-294)
Revenue
$47.88M*
▲ 196.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-02
Kymera Therapeutics, Inc. (KYMR) Q3 2023 Earnings Call Transcript
Revenue
$4.73M
▼ 50.5% YoY
Diluted EPS
$-0.90
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Kymera Therapeutics, Inc. (KYMR) Q2 2023 Earnings Call Transcript
Revenue
$16.51M
▲ 43.4% YoY
Diluted EPS
$-0.67
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Kymera Therapeutics, Inc. (KYMR) Q1 2023 Earnings Call Transcript
Revenue
$9.47M
▼ 1.6% YoY
Diluted EPS
$-0.70
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-01-10
Kymera Therapeutics, Inc. (KYMR) Q4 2022 Earnings Call Transcript
Revenue
$16.14M*
▲ 5.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Kymera Therapeutics, Inc. (KYMR) Q3 2022 Earnings Call Transcript
Revenue
$9.55M
▼ 53% YoY
Diluted EPS
$-0.79
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-09
Kymera Therapeutics, Inc. (KYMR) Q2 2022 Earnings Call Transcript
Revenue
$11.51M
▼ 37.8% YoY
Diluted EPS
$-0.78
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Kymera Therapeutics, Inc. (KYMR) Q1 2022 Earnings Call Transcript
Revenue
$9.62M
▼ 48.6% YoY
Diluted EPS
$-0.71
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–25 of 25 webcasts
Key facts CIK 1815442 CUSIP 501575104 13F (30d) 320 filings 293 filers Visit website Investor relations